Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lutetium Lu-177 JH020002
- Development stage
- Phase 2
- Lead developer
- Bivision Pharmaceuticals
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lutetium Lu-177 JH020002 is a targeted radiopharmaceutical under development for the treatment of prostate specific membrane antigen-positive (PSMA+) metastatic castration-resistant prostate cancer (mCRPC) and potentially other forms of prostate cancer. It is a novel targeted radionuclide therapy (TRT) designed to deliver radiation directly to cancer cells expressing PSMA, causing DNA damage and cell death. Preclinical data suggest improved efficacy over currently approved agents (such as Pluvicto) in models with both high and mid-to-low PSMA expression. Clinical trials are ongoing to assess its safety, pharmacokinetics, dosimetry, and efficacy in adults with advanced prostate cancer.[3][1]
- Other names
- lutetium Lu-177 JH020002
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on lutetium Lu-177 JH020002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lutetium Lu-177 JH020002.